Development-stage drug development company, Parion Sciences, just announced a generous donation from the Cystic Fibrosis Foundation Therapeutics (CFFT) organization worth $3 million. This funding will be allotted to further research on the company’s latest experimental product for cystic fibrosis (CF) — a genetic and incurable disease of the mucous glands that can lead to progressive lung failure.
Parion’s latest candidate for CF treatment, P-1037, will be entering Phase II of clinical trials. Recruitment of participants will begin early next year. The drug is classified as an epithelial sodium channel (ENaC) inhibitor, formulated to stimulate secretion of fluid along the lungs’ mucosal surface in order to restore and maintain hydration. Ensuring hydration in mucus buildup will facilitate more efficient airway clearance, reduce the risk for infection, and enhance overall pulmonary function.
Additionally, the CFFT donated $967,000 for the company’s cystic fibrosis transmembrane conductance regulator (CFTR) corrector studies, which act on the FF508del CFTR protein, making it more stable and efficient in chloride ion transport. Parion is currently working on developing an oral formulation for their CFTR corrector, indicated for the management of other CF-damaged organs.
Cystic fibrosis affects many people all over the world. It can be a debilitating disease that often times leaves patients feeling hopeless during the long wait for a cure. Despite the harsh reality CF patients face everyday, a good number of them have decided to become an inspiration to others by doing what they can to pursue passions and live a full life. One of these CF role models is 27-year-old Wiktoria Lachowski — a talented opera singer with advanced cystic fibrosis and determination to become a world famous singer.